BMO Capital Believes Boston Scientific Corp (NYSE: BSX) Won’t Stop Here

By Carrie Williams

BMO Capital analyst Joanne Wuensch reiterated a Buy rating on Boston Scientific Corp (NYSE: BSX) on October 11 and set a price target of $30. The company’s shares closed yesterday at $29.43, close to its 52-week high of $29.54.

According to TipRanks.com, Wuensch is a 4-star analyst with an average return of 7.4% and a 69.5% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Baxter International, and Edwards Lifesciences.

Currently, the analyst consensus on Boston Scientific Corp is Strong Buy and the average price target is $31.29, representing a 6.3% upside.

In a report issued on September 27, SunTrust Robinson also reiterated a Buy rating on the stock with a $34 price target.

Boston Scientific Corp’s market cap is currently $40.33B and has a P/E ratio of 50.74. The company has a book value ratio of 5.5747.

Based on the recent corporate insider activity of 150 insiders, corporate insider sentiment is negative on the stock. Most recently, in August 2017, John Bradley Sorenson, the SVP, Manuf & Sup Chn of BSX sold 7,900 shares for a total of $208,323.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. Its products and technologies are used to diagnose or treat medical conditions, including heart, digestive, pulmonary, vascular, urological, women’s health and chronic pain conditions.